Medical Disclaimer
Updated: — medical terminology and interaction examples clarified.
This site is educational. It is not medical advice. Do not use it to diagnose, treat, or make medication decisions. Talk to a licensed clinician.
What Peptide Dossier is
Peptide Dossier is a reference site covering peptides, GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide, and others), and related compounds. Tirzepatide is a dual GIP/GLP-1 receptor agonist, as described in the Zepbound labeling.
We compile information from peer-reviewed research, FDA filings, clinical practice guidelines, manufacturer labeling, and reputable secondary sources. Every guide on this site is written to help a curious adult understand the landscape.
What it is not
Peptide Dossier is not a doctor, pharmacist, nurse, or other healthcare professional. It cannot take a history, examine you, review your labs, or weigh your medication list. It cannot prescribe. Nothing on this Site should be interpreted as:
- A diagnosis of any medical condition
- A recommendation to start, stop, or change a medication
- An endorsement of any compound for any specific person
- A substitute for evaluation by a licensed clinician
- Legal advice about the regulatory status of any peptide
Why this matters for peptides specifically
Peptides occupy a complicated space. Some are FDA-approved prescription products, including Ozempic (semaglutide) and Zepbound (tirzepatide). Prescription-product examples also include Pitocin (oxytocin) and octreotide; a molecule name alone does not establish the approved uses of a particular product.
Some are compounded under 503A or 503B authority with different, conditional requirements. Compounded drugs can sometimes address medical needs, but the FDA explains that they are not FDA-approved or pre-reviewed for safety, effectiveness, or quality before marketing; compounding status is not FDA approval. The FDA's compounding provisions describe the conditions that apply to those pathways.
Some are sold as "research chemicals"; a research-only label is not a quality guarantee. Check the evidence and current regulatory requirements separately for BPC-157, TB-500, and ipamorelin rather than assuming they share the same status.
Although often discussed alongside peptides, MK-677 (ibutamoren) is a non-peptide small-molecule ghrelin-receptor agonist.
When reading about dosing ranges, half-lives, side effects, or injection technique, check the cited study or product instructions for the population, formulation, and route involved. These discussions are context, not a personal treatment plan. Ask your clinician how your age, medical history, other medicines, and kidney or liver function affect the choice of product and monitoring.
Drug interactions and comorbidities
Warnings differ between products. Ozempic labeling identifies increased hypoglycemia risk with insulin or sulfonylureas and says use is not recommended in severe gastroparesis. Gastroparesis is a medical condition, not itself a drug interaction.
If anesthesia or deep sedation is planned, tell the treating team; this page does not supply a universal stop interval. Zepbound labeling includes a product-specific oral-hormonal-contraception precaution: use a nonoral method or add a barrier method for four weeks after starting and for four weeks after each dose escalation. Do not generalize that precaution to every GLP-1 medicine.
Ozempic and Zepbound labeling describe rodent thyroid-tumor findings whose relevance to humans is unknown; product-label contraindications for a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 are not proof that these medicines cause human thyroid cancer. Pancreatitis remains a label warning, not a guaranteed outcome.
Before considering a compound that affects growth-hormone pathways, ask a clinician to assess the evidence for that specific compound alongside your diabetes or cancer history. If you have an existing condition, take prescription medications, are pregnant or nursing, or are planning surgery, do not act on anything on this Site without clinician review.
Emergencies
If you are experiencing a medical emergency, call 911 (in the United States) or your local emergency number immediately. Do not use this Site for emergency guidance.
Sources and errors
We cite primary sources where possible. Medical knowledge evolves; FDA guidance changes; clinical trials report new results. If you rely on a specific claim from this site for a real decision, verify it against the underlying source or a current clinician. If you find an error, let us know and we will correct it.
Provider referrals
We receive no compensation for referrals or links. Rankings reflect editorial judgment. A favorable provider mention does not establish that a treatment is appropriate for your situation; prescription eligibility requires a clinician's assessment.
See also: Privacy Policy and Terms of Use.